Malignancy and its associated management have long been recognised as significant risk factors for venous thromboembolism (VTE). The risk of VTE in cancer patients is increased by seven-fold, with approximately 5-20% of all cancer patients will develop VTE. 1 Complex aetiology involving prothrombotic state of underlying tumour cells and the haemostatic sideeffects of oncological treatments including cytotoxic drugs, hormonal therapy, radiotherapy and surgery lead to difficulties in defining optimal VTE prevention and management in cancer patients. Nonetheless, the consequential morbidity and mortality dictate that its amelioration must remain a priority for clinicians.
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Currently, low-molecular weight heparins (LMWHs) are the preferred anticoagulants for the prophylaxis and treatment of VTE in cancer patients. [1] [2] [3] Meanwhile, vitamin K antagonists (VKA) such as warfarin are advocated where high cost or poor renal function precludes the use of LMWHs in the treatment of VTE. 1 Considering long-term treatment, LMWH demonstrates superior efficacy to warfarin. 1, 2 Recent meta-analysis by the Cochrane Collaboration on seven randomised controlled trials (RCTs) comparing LMWHs with VKAs found a statistically significant reduction in VTE (hazard ratio 0.47; 95% confidence interval, CI 0.32 to 0.71), but no significant difference in survival benefit, bleeding and thrombocytopenia. 2 In addition, LMWHs hold a myriad of practical advantages over VKAs including fewer drug interactions, avoidance of frequent venepuncture and predictable effect especially in those with risk of gastrointestinal tract disturbance such as nausea, vomiting, diarrhoea and malabsorption. However, disadvantages include bruising and pain from daily injection, potential cost associated with requirement for district nurses and increased risk of thrombocytopenia and osteoporosis. The main advantages of VKAs are that they are effective in preventing recurrent VTE and are time proven. 3 However, cancer patients have numerous complicating factors such that achieving and maintaining a therapeutic international normalised ratio is challenging; frequent venepuncture becomes unavoidable.
Over recent years, several novel direct oral anticoagulant (DOAC) agents have emerged which specifically target key molecules within the coagulation cascade. These mainly include factor Xa inhibitors (e.g. rivaroxaban, apixaban and edoxaban) and direct thrombin inhibitors (e.g. dabigatran). Results emerging from phase three trials for both classes appear promising in the treatment of VTE. Both the EINSTEIN-DVT and EINSTEIN-PE RCTs demonstrated noninferiority of rivaroxaban when compared with standard treatment (enoxaparin for 5-10 days followed by an oral VKA) in preventing recurrent VTE. 4, 5 In a subgroup analysis of 207 (6%) and 223 (4.6%) cancer patients enrolled in the EINSTEIN-DVT and EINSTEIN-PE, respectively, similar results were found. Moreover, in the EINSTEIN-Ext trial, the superiority of rivaroxaban over placebo in long-term prevention of recurrent VTE was reported. 4 Similar non-inferiority of apixaban and edoxaban when compared with standard treatment was reported in the AMPLIFY and HOKUSAI trials, respectively. [6] [7] [8] The bleeding risk with the factor Xa inhibitors does not appear significantly different compared with LMWHs and warfarin. [4] [5] [6] [7] [8] With regard to dabigatran, the RE-COVER and RE-MEDY trials demonstrated it to be non-inferior to warfarin in the prevention of recurrent VTE and VTE-related death in acute and long term, respectively. 9,10 Similar conclusions were drawn from the subgroup analysis of 121 (4.7%) cancer patients in the RE-COVER study. 9 Dabigatran was shown to have similar safety profile including bleeding although with more adverse events leading to drug discontinuation and dyspepsia when compared with warfarin in the RE-COVER study. 9 Meanwhile, in the RE-MEDY study, dabigatran demonstrated a trend toward a lower risk of bleeding but significantly more acute coronary syndrome when compared to warfarin. 10 A recent meta-analysis performed subgroup Academic Section of Vascular Surgery, Division of Surgery, Department of Surgery & Cancer, Imperial College London, Charing Cross Hospital, London, UK analysis of cancer patients in six RCTs comparing the efficacy and safety of DOACs to VKAs for the initial treatment of VTE. 11 The meta-analysis pooled a population of 1132 cancer patients from these six RCTs and reported the incidence of recurrent VTE in 3.9% of patients on DOACs compared to 6.0% of patients on conventional therapy (odds ratio 0.63; 95% CI 0.37-1.10). Major bleeding occurred in 3.2% and 4.2% of patients receiving DOACs and conventional treatment, respectively (OR 0.77; 95% CI 0.41-1.44). 11 Besides VTE treatment, recent RCTs including the MAGELLAN (8101 patients, of whom 584 had history of cancer) and ADOPT (6528 patients, of whom 632 had history of cancer) trials demonstrated similar efficacy of DOACs (rivaroxaban and apixaban, respectively) when compared with LMWH (enoxaparin) in VTE prophylaxis in hospitalised patients with acute medical illness. 12, 13 Furthermore, the ADVOCATE trial which was a multi-centre, phase 2 double-blinded pilot RCT concluded that apixaban when compared with placebo was well tolerated and acceptable for the prevention of VTE in ambulatory subjects undergoing first-line and second-line chemotherapy for advanced metastatic cancer. 14 All DOACs share similar practical advantages in that they are administered orally with fixed dose and do not require regular monitoring due to predictable pharmacological profiles with apparently minimal food and drug interactions. However, there are noteworthy disadvantages largely centred on the limited evidence available. Whilst initial trials are encouraging, the agents are not time proven and evidence is scarce regarding long-term side-effects or possible interactions with chemotherapy agents and other commonly use drugs in cancer patients. For example, rivaroxaban and apixaban interact with drugs that induce or inhibit CYP3A4 and P-glycoprotein (P-gp), which are involved in their metabolism. 15 These drugs include rifampicin, azoles, selective serotonin re-uptake inhibitors, diltiazem, phenytoin, dexamethasone, doxorubicin and vinblastine. 15 Furthermore, the elimination of rivaroxaban and apixaban is through kidney and liver, while dabigatran is predominantly excreted by renal. Therefore, their use in patients with kidney and/or liver impairment may increase the risk of bleeding. 15 Due to the predictable pharmacokinetics of DOACs, their anti-coagulant activity of DOACs lasts for about 24-30 h. Therefore, their efficacy may be compromised in patients who omit a dose due to nausea and vomiting (which is not uncommon in patients with cancer). 15 There is also very little reported about the efficacy or safety of these drugs in children or pregnant women. Furthermore, there is no antidote to reverse their anticoagulation effect if major bleeding occurs or emergency invasive procedure is required, and lack of assay to measure their anticoagulation level if treatment failure or non-compliance is suspected.
In addition to exploring wider implications surrounding these drugs, their novel nature provides multiple avenues for future research in cancer patients. Further study of the basic and translational science should be undertaken to allow for more precise and highly specific targeting, in addition to investigating auxiliary ways to reduce adverse effects and unwanted interactions with various chemotherapy agents. Thus, far there have only been a few hundred cancer patients included in the phase 3 trials for the DOACs. The subgroup analysis of these trials must be interpreted with caution as they were not designed and adequately powered for cancer patients. Moreover, patients with reduced life expectancy and end-organ dysfunction, which would have likely to include a significant number of cancer patients, were excluded in these trials. As a result, cancer patients included in these trials were probably less prothrombotic and had more favourable cancer prognosis. 1 Furthermore, the clinical benefits or non-benefits of DOACs to different subgroups of cancer patients such as type of malignancy, disease stage, ambulatory patients receiving chemotherapy, patients receiving different oncological therapies need to be established. Clearly, there is a dire need for RCTs specifically comparing DOACs with standard treatment for prophylaxis and treatment of VTE in general and different subgroups of cancer patients. The quality-of-life of the cancer patients treated with the DOACs, and their cost-effectiveness will also need to be established with good quality clinical trials.
Effective management of VTE in cancer patients requires multi-disciplinary input. Phlebologists and vascular surgeons, alongside their haematology, oncology and surgical colleagues have a crucial role to play. A substantial VTE may present to vascular surgeons and phlebologists as the first demonstration of occult malignancy. Vascular advice may also be sought in the management of massive (e.g. iliofemoral and caval thrombus) or recurrent VTE which are not uncommon in cancer patients. Phlebologists and vascular surgeons should be actively involved in contributing to local, national and international guidelines on overall prevention and management of VTE, particularly in complex patients such as those with active malignancy. A further critical role of the phlebologist is to engage with highquality basic science and clinical research to discover more specific and effective novel anticoagulants, as well as understand and establish the clinical roles and costeffectiveness of DOACs in cancer patients.
In summary, optimal management of malignancyassociated VTE remains complicated with a delicate balance between efficacy, bleeding risk and ease of use in a population of often fragile patients. Whilst it is not yet clear whether DOACs are superior to current best practice, trials to date have shown promising outcomes and further RCTs, specific to cancer patients should be pursued. In the meantime, clinical judgement should be used alongside current guidelines to ensure individualised treatment plans are created, which reflect the diverse nature of these complicated patients.
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